Key Highlights

  • The net loss for the third quarter narrowed to USD 3.16 million, or USD 0.18 a share, from USD 3.56 million, or USD 0.28, as Research and Development expense fell 73% to USD 0.32 million.
  • Cash and cash equivalents were USD 11.5 million at September 30, 2026, against USD 24.7 million at year-end, and management expects them to fund operations only through the first quarter of 2027.
  • The filing states there is substantial doubt about the company's ability to continue as a going concern, with an accumulated Deficit of USD 197.8 million and nine-month operating cash outflow of USD 19.1 million.
  • Dispensing of DARE to PLAY Sildenafil Cream is expected to start in November 2026 in 28 states, though the company does not expect the Revenue to be material in 2026.

A Narrower Loss Built on Grant-Funded Research

Daré Bioscience (NASDAQ:DARE) filed its Quarterly Report on November 16, 2026, covering the three months ended September 30, 2026. The net loss was USD 3,157,936 versus USD 3,562,766, a decline of 11%, while the loss from operations eased to USD 3.09 million from USD 3.67 million. Revenue was only USD 47,628, up from USD 2,262, mostly research and development services performed under agreements with a foundation. The company focuses on women's health, from contraception to menopause, and now pairs FDA development with a Section 503B compounding route. Selling, general and administrative expense edged up 6% to USD 2.64 million, including a USD 0.2 million write-down of deferred offering costs.

Going-Concern Doubt Meets a USD 11.5 Million Cash Balance

Cash and cash equivalents fell to USD 11,531,684 from USD 24,711,356 at December 31, 2025, and Working Capital was about USD 3.2 million. Deferred grant funding of USD 11.2 million, mainly for the DARE-LARC1 program, the Ovaprene Phase 3 study and DARE-HPV, sits on the Balance Sheet as a liability. Management believes existing cash covers operating needs, including the DARE to PLAY launch, through the first quarter of 2027. The accumulated deficit was USD 197.8 million, and the company says additional equity, Debt or grant capital could dilute holders. Shares outstanding were 19,669,083 as of November 13, 2026, and the nine-month loss was USD 9.1 million, or USD 0.59 a share.

Ovaprene Study and the DARE to PLAY Launch Set the Next Tests

The pivotal Phase 3 study of Ovaprene, a hormone-free monthly contraceptive ring, is still enrolling. An independent safety committee reviewed 399 subjects and 1,789 menstrual cycles, and the FDA approved a protocol amendment in August 2026 while cautioning that it may not Yield enough evidence for approval. The company intends to keep talking with the agency. On the commercial side, DARE to PLAY dispensing is expected to begin in November 2026, and a consumer probiotic, Flora Sync LF5, launched in June 2026. A USD 0.9 million grant payment arrived on November 13, 2026. Risks include dilution, trial design disputes and slow early sales.

Where Things Stand

The cash covers roughly one more quarter beyond year-end, not much longer, by management's own estimate. Daré Bioscience (NASDAQ:DARE) held USD 11.5 million against a USD 3.2 million quarterly loss, but nine-month cash burn of USD 19.1 million and a going-concern warning mean new capital is likely needed in 2027. Grant funding of USD 11.2 million and lower research spending help, and the loss narrowed. Next markers are the DARE to PLAY dispensing start, FDA talks on the Ovaprene study design and any financing announcement.